CN106236956A - A kind of Chinese medicine preparation treating fungal keratitis - Google Patents
A kind of Chinese medicine preparation treating fungal keratitis Download PDFInfo
- Publication number
- CN106236956A CN106236956A CN201610716216.7A CN201610716216A CN106236956A CN 106236956 A CN106236956 A CN 106236956A CN 201610716216 A CN201610716216 A CN 201610716216A CN 106236956 A CN106236956 A CN 106236956A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- radix
- group
- medicine preparation
- fungal keratitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a kind of Chinese medicine preparation treating fungal keratitis, belong to technical field of Chinese medicines.Inventor is in clinical practice for many years, the cause of disease according to fungal keratitis, select Chinese medicine Fructus Ulmus preparatium, Radix Brassicae rapae, Radix Ampelopsis delavayanae, Radix Antenoronis Filiformis, Herba Sericocalycis Chinensis, Herba Menthae Rotundifoliae, make decoction, bright through clinical trial checking, owing to we's compatibility has obvious synergistic function, total effective rate reaches 100.0%, therapeutic effect is substantially better than each single medicinal material group of matched group, particularly this prescription also preferable curative effect to night sweat.
Description
Technical field
The present invention relates to technical field of Chinese medicines, particularly relate to a kind of Chinese medicine preparation treating fungal keratitis.
Background technology
Over nearly 20 years, the patient of fungal keratitis is continuously increased, and has become as important blinding keratopathy.At present
Think that increasing of fungal keratitis is applied mainly due to antibiotic and the extensive of glucocorticoid, change the micro-of eye local
Environment, and pesticide a large amount of use, and to cause soil fungi ecological balance to destroy caused, simultaneously with ophthalmology worker to fungoid
The further investigation of keratitis and constantly recognizing, improve clinical diagnosis level also has relation.Fungus is only second to antibacterial, is usual
The pathogen that purulence corneal ulcer is the 2nd.The most common in the area of humid tropics weather.The cause of disease of fungal keratitis is a lot,
Worn by vegetalitas wound, corneal contact lens, immunosuppressive condition draws after corticosteroid hormone and immunosuppressant use
Rise.Chinese medicine compound has superiority in terms of the regulation of whole body function and immunomodulating very much.Applicant through clinical practice for many years,
Constantly exploratory development, makes a kind of Chinese medicine preparation treating fungal keratitis, and through clinical trial, therapeutic effect is preferable,
Clinic popularization and application.
Summary of the invention
It is an object of the invention to provide a kind of Chinese medicine preparation treating fungal keratitis.Research shows the poison of fungus itself
Power i.e. aggressivity and body defenses are the two big factors that fungal infection occurs extremely.The suitable heat-clearing and toxic substances removing of Chinese traditional treatment, wind dispelling of invigorating blood circulation,
Liver heat removing and eyesight improving, hard masses softening and resolving.
It is an object of the invention to be achieved through the following technical solutions, the Chinese medicine preparation of this treatment fungal keratitis be by
Following Chinese medicine is made: Fructus Ulmus preparatium 7-11 part, Radix Brassicae rapae 20-30 part, Radix Ampelopsis delavayanae 12-18 part, Radix Antenoronis Filiformis 30-40 part, Herba Sericocalycis Chinensis 20-30
Part, Herba Menthae Rotundifoliae 10-16 part.
Preferred: Fructus Ulmus preparatium 9 parts, Radix Brassicae rapae 25 parts, Radix Ampelopsis delavayanae 15 parts, Radix Antenoronis Filiformis 35 parts, Herba Sericocalycis Chinensis 25 parts, Herba Menthae Rotundifoliae 13
Part.
Preparation method: traditionally make decoction.
Fang Zhong: Fructus Ulmus preparatium killing insect and eliminating accumulation, there is wide spectrum press down fungicidal action；Radix Brassicae rapae appetizing the therapeutic method to keep the adverse QI flowing downwards, eliminating damp, detoxifying, to antibacterial,
Funguses etc. have inhibitory action in various degree；Radix Ampelopsis delavayanae dispelling, collateral-activating, subduing swelling and detoxicating, hemostasia and promoting granulation；Radix Antenoronis Filiformis dissipating blood stasis for subsidence of swelling,
Pain relieving, removing toxic substances promoting the circulation of QI；Herba Sericocalycis Chinensis diuresis removing toxic substances, antiinflammatory；Herba Menthae Rotundifoliae dissipates wind heat, detumescence poison, eyesight improvement powder medicine expectorant.
Detailed description of the invention
Embodiment one: weigh Fructus Ulmus preparatium 7g, Radix Brassicae rapae 20g, Radix Ampelopsis delavayanae 12g, Radix Antenoronis Filiformis 30g, Herba Sericocalycis Chinensis 20g, Herba Menthae Rotundifoliae
10g, traditionally makes decoction.
Embodiment two: weigh Fructus Ulmus preparatium 9g, Radix Brassicae rapae 25g, Radix Ampelopsis delavayanae 15g, Radix Antenoronis Filiformis 35g, Herba Sericocalycis Chinensis 25g, Herba Menthae Rotundifoliae
13g, traditionally makes decoction.
Embodiment three: weigh Fructus Ulmus preparatium 11g, Radix Brassicae rapae 30g, Radix Ampelopsis delavayanae 18g, Radix Antenoronis Filiformis 40g, Herba Sericocalycis Chinensis 30g, Herba Menthae Rotundifoliae
16g, traditionally makes decoction.
Toxicity test
1, laboratory animal cleaning grade healthy SD female rats 80, weight (210 ± 8) g, as chronic toxicity；
The female white mice in cleaning grade health Kunming 60, weight (28 ± 4) g, as acute toxicological experiment.Feed with normal diet, general
Logical drinking-water.Room temperature controls in (25 ± 2) DEG C, humidity (50 ± 2) %, natural lighting.
2, acute toxicological experiment is according to (Chinese medicine, researches on natural drugs registration service manual), selects cleaning grade health Kunming
Female white mice 60, is randomly divided into 2 groups, Chinese drug-treated group and each 30 of blank group.Chinese drug-treated group is rolled over by adult normal's oral dose
It is counted as the dosage of white mice, gavages Chinese medicine every day 1 time.Blank group is given 1mL/20g weight 0.9% sodium chloride injection and is filled
Clothes.
3, long term toxicity test cleaning grade healthy SD female rats 80, is randomly divided into 4 groups, Normal group and Chinese medicine
Group little, in, heavy dose of each 20.Matched group gives 1ml/20g weight 0.9% sodium chloride injection, Chinese drug-treated group little, in,
Heavy dose of group is that adult normal consumption is converted to the 5 of rat dosage, 15,50 times, is gastric infusion, every day 1 time, experimental period
It it is 3 months.
4, acute toxicity testing result white mice nothing in being administered 7d is dead, to observation post administration mice outward appearance, hair color, light
Pool is normal, and social behavior, reaction are all normal, ingests, drains normally.Manually put to death dissection after 7d, observe its heart, liver, spleen
Dirty, lungs, kidney, brain, ovary, uterus are showed no exception.Pathological examination: dyeing in single-minded Yihong of Lignum Sappan (HE), Chinese drug-treated group is dirty
Device smooth surface, in order, cell size, form are normal in organizational structure arrangement, and the dyeing of endochylema, karyon is clear, with blank group
Comparing difference not statistically significant (P ＞ 0.05).
5, chronic toxicity result Chinese drug-treated group little, in, heavy dose of group and the outward appearance of rats in normal control group, hair color,
Social behavior, zest etc. and to surrounding, food, the equal not statistically significant of comparing difference (P ＞ 0.05) such as interest of water.
(P ＜ 0.05) is increased before the experiment of weight the most relatively this group after 4 groups of rat experiments, but the equal nothing of weight comparing difference after 4 groups of experiments
Statistical significance (P ＞ 0.05), blood cytology index, blood biochemical analysis index, important organ coefficient ratio after 4 groups of rat experiments
Compared with the equal not statistically significant of difference (P ＞ 0.05).At 4 groups of rats, after death important organ row staining pathologic section checks, HE dyes.
In order, cell size, form are normal for the arrangement of Chinese drug-treated group Rats Organs and Tissues organizational structure, and the dyeing of endochylema, karyon is clear, with normal control
Group comparing difference not statistically significant (P ＞ 0.05).
6, toxicity test shows, the Chinese medicine preparation of the treatment fungal keratitis of the present invention has no toxic reaction after being administered.
Clinical data
1, case selection is as the Chinese medicine preparation for the treatment of fungal keratitis, selects the fungal keratitis patient made a definite diagnosis
240 example clinical observations, wherein male 124 example, women 116 example, age 26～65 years old, 40.5 years old mean age；Patient divides at random
Becoming 8 groups, each group course of disease of case, degrees of symptoms are basically identical, without significant difference, have comparability.
Patient know the inside story and voluntarily on the basis of, only take Fructus Ulmus preparatium single medicinal material group and be A group, only take Radix Brassicae rapae single medicinal material group and be
B group, only take Radix Ampelopsis delavayanae single medicinal material group and be C group, only take Radix Antenoronis Filiformis single medicinal material group and be D group, only take Herba Sericocalycis Chinensis single medicinal material
Group is E group, only take Herba Menthae Rotundifoliae single medicinal material group is F group, take the present invention is treatment group by embodiment two preparation group, is used often
Rule therapy is matched group.Each group is compared not statistically significant (P ＞ 0.05) in the physical data such as age, sex, has comparability.
2, Therapeutic Method treatment group is taken and is treated by the prepared medicament of embodiment of the present invention two；Matched group uses
Chibroxin, instills in eyelid, one time 1～2,3～6 times on the one；Weigh A, B, C, D, E, F each single medicinal material group respectively
Weight, traditionally make medicament and treated, each group one week is a course for the treatment of, and it is laggard that each group patient all treats two courses for the treatment of
Row comparitive study.
3, efficacy determination (1) is cured: the irritation such as sensation of dryness, foreign body sensation all disappears, and eye recovers normal；(2) aobvious
Effect: the irritation such as sensation of dryness, foreign body sensation substantially alleviates, and eye is clearly better；(3) effective: sensation of dryness, foreign body sensation etc. stimulate disease
Shape has alleviated, and eye has taken a turn for the better；(4) invalid: by the irritation such as sensation of dryness, foreign body sensation after treatment without alleviating or adding
Weight.
4, therapeutic outcome such as following table
| Group | Number of cases | Dose (g) | Cure | Effective | Effectively | Invalid | Side effect | Total effective rate (%) |
| A | 30 | 160 | 1 | 2 | 1 | 26 | 5 examples | 13.3 |
| B | 30 | 160 | 2 | 2 | 2 | 24 | 4 examples | 20.0 |
| C | 30 | 160 | 1 | 3 | 1 | 25 | 6 examples | 13.3 |
| D | 30 | 160 | 2 | 1 | 0 | 27 | 3 examples | 10.0 |
| E | 30 | 160 | 1 | 2 | 1 | 26 | 3 examples | 13.3 |
| F | 30 | 160 | 3 | 1 | 2 | 24 | 2 examples | 20.0 |
| Treatment group | 30 | 122 | 20 | 6 | 4 | 0 | 0 example | 100.0 |
| Matched group | 30 | Convention amount | 13 | 7 | 6 | 4 | 0 example | 86.7 |
By the dose of single medicinal material each in upper table, do toxicity test by the above-mentioned method doing toxicity test respectively, experiment tie
Fruit understands each single medicinal material group and is nontoxic level.By above clinical data, although treatment group takes less dose, but
Achieving preferable therapeutic effect, total effective rate is higher than each single medicinal material total effective rate sum, also significantly better than matched group, more gratifying
Be toxicity reduce, have no side effect appearance, it follows that each medicine under synergistic function to the side of beneficially human health
To development, clinic popularization and application.
When treatment group patient is followed up a case by regular visits to by we, wherein there are 3 example readmes " after taking the preparation of the present invention, the most very
Bacterium property keratitis has obtained rehabilitation, and night sweat symptom might as well ".After obtaining this message, 20 examples are suffered from not by immediately
With degree night sweat patient, using the Chinese medicine preparation that embodiment of the present invention two prepares, every day, potion, divided the side sooner or later taken for twice
Method is treated.Curative effect judging standard is fully recovered: night sweat stops completely, and concomitant symptom disappears substantially, nothing recurrence in 1 year after drug withdrawal；Aobvious
Effect: night sweat stops substantially, and concomitant symptom has been alleviated, nothing recurrence in 6 months after drug withdrawal；Invalid: night sweat and concomitant symptom are all without changing
Kind.Result: in 20 example patients, 12 examples of fully recovering (60%), effective 7 examples (35%), invalid 1 example (5%), total effective rate by recovery from illness and
Effective meter, is 95%.It follows that take the Chinese medicine preparation of the present invention, not only treatment fungal keratitis is evident in efficacy, and
Night sweat is had good therapeutic effect, clinic popularization and application.
Claims (2)
1. the Chinese medicine preparation treating fungal keratitis, it is characterised in that this Chinese medicine preparation is made up of following Chinese medicine: overgrown with weeds
Sprout 7-11 part, Radix Brassicae rapae 20-30 part, Radix Ampelopsis delavayanae 12-18 part, Radix Antenoronis Filiformis 30-40 part, Herba Sericocalycis Chinensis 20-30 part, Herba Menthae Rotundifoliae 10-16
Part.
A kind of Chinese medicine preparation treating fungal keratitis, it is characterised in that this Chinese medicine preparation is
It is made up of following Chinese medicine: Fructus Ulmus preparatium 9 parts, Radix Brassicae rapae 25 parts, Radix Ampelopsis delavayanae 15 parts, Radix Antenoronis Filiformis 35 parts, Herba Sericocalycis Chinensis 25 parts, Herba Menthae Rotundifoliae 13
Part.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610716216.7A CN106236956A (en) | 2016-08-15 | 2016-08-15 | A kind of Chinese medicine preparation treating fungal keratitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610716216.7A CN106236956A (en) | 2016-08-15 | 2016-08-15 | A kind of Chinese medicine preparation treating fungal keratitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106236956A true CN106236956A (en) | 2016-12-21 |
Family
ID=57596088
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610716216.7A Pending CN106236956A (en) | 2016-08-15 | 2016-08-15 | A kind of Chinese medicine preparation treating fungal keratitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106236956A (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1157155A (en) * | 1996-12-27 | 1997-08-20 | 王双 | Chinese patent drug for curing monovesicle viral keratitis |
| CN101007054A (en) * | 2007-01-26 | 2007-08-01 | 马雪芳 | Drug for treating cataract |
| CN102697851A (en) * | 2012-07-12 | 2012-10-03 | 马雪芳 | Medicament for treating ocular surface disease |
| CN103239591A (en) * | 2013-04-28 | 2013-08-14 | 王伟林 | Medicine for treating eye diseases |
| CN103301431A (en) * | 2013-06-09 | 2013-09-18 | 刘召英 | Traditional Chinese medicinal preparation for treating glaucoma and preparation method thereof |
| CN103893448A (en) * | 2014-04-25 | 2014-07-02 | 王太霞 | Medicine for treating fundus hemorrhage and preparation method thereof |
| CN104056068A (en) * | 2014-07-01 | 2014-09-24 | 李坚恩 | Traditional Chinese medicine eye drops for treating chronic conjunctivitis |
-
2016
- 2016-08-15 CN CN201610716216.7A patent/CN106236956A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1157155A (en) * | 1996-12-27 | 1997-08-20 | 王双 | Chinese patent drug for curing monovesicle viral keratitis |
| CN101007054A (en) * | 2007-01-26 | 2007-08-01 | 马雪芳 | Drug for treating cataract |
| CN102697851A (en) * | 2012-07-12 | 2012-10-03 | 马雪芳 | Medicament for treating ocular surface disease |
| CN103239591A (en) * | 2013-04-28 | 2013-08-14 | 王伟林 | Medicine for treating eye diseases |
| CN103301431A (en) * | 2013-06-09 | 2013-09-18 | 刘召英 | Traditional Chinese medicinal preparation for treating glaucoma and preparation method thereof |
| CN103893448A (en) * | 2014-04-25 | 2014-07-02 | 王太霞 | Medicine for treating fundus hemorrhage and preparation method thereof |
| CN104056068A (en) * | 2014-07-01 | 2014-09-24 | 李坚恩 | Traditional Chinese medicine eye drops for treating chronic conjunctivitis |
Non-Patent Citations (3)
| Title |
|---|
| 南京中医药大学编著: "《中药大辞典》", 31 March 2006, 上海科学技术出版社 * |
| 张健等: "《眼科汤头歌诀》", 30 April 2009, 山西科学技术出版社 * |
| 张海滨等: ""真菌性角膜炎的综合治疗"", 《现代实用医学》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103933124B (en) | The Chinese herb medicine eye paste of a kind of remitting vision fatigue and preparation technology thereof | |
| CN106039109A (en) | Traditional Chinese medicinal liquor for preventing and treating cold dampness accumulation pattern rheumatoid arthritis | |
| CN105326954B (en) | A kind of Chinese medicine composition and preparation method thereof for treating blear-eye | |
| CN1160091C (en) | Medicine for treating ophthalmopathy | |
| CN106236956A (en) | A kind of Chinese medicine preparation treating fungal keratitis | |
| CN107115408A (en) | It is a kind of to reduce the medicine of methotrexate (MTX) side effect | |
| CN108295168B (en) | Traditional Chinese medicine composition for treating post-stroke depression | |
| CN107648397B (en) | Traditional Chinese medicine composition for treating liver-kidney yin deficiency and preparation method and application thereof | |
| CN105194352B (en) | A kind of Chinese medicine composition and preparation method thereof improving learning and memory | |
| CN104324139B (en) | A kind of pharmaceutical composition treating xerophthalmia | |
| CN105998843A (en) | Traditional Chinese medicine preparation for treating recurring type dental ulcers | |
| CN106361853A (en) | Traditional Chinese medicine preparation for treating liver-and-stomach-dampness-heat chronic gastritis | |
| CN106138486A (en) | A kind of Chinese medicine preparation treating fungal keratitis | |
| CN106236958A (en) | A kind of Chinese medicine preparation treating viral keratitis | |
| CN105770416A (en) | Traditional Chinese medicine preparation containing Folium artemisiae argyi and for treating eye redness and swelling and pain and preparation method thereof | |
| CN107693614A (en) | A kind of Chinese medicine preparation for treating syndrome of qi stagnation and blood stasis intestinal tuberculosis | |
| CN105031065A (en) | Traditional Chinese medicine for treating acute suppurative otitis media and preparation method of traditional Chinese medicine | |
| CN106421554A (en) | Traditional Chinese medicine preparation for treating tonsillitis | |
| CN106038908A (en) | Traditional Chinese medicinal preparation for treating cerebral concussion | |
| CN106309855A (en) | Traditional Chinese medicine preparation for treating periodontitis | |
| CN106266172A (en) | A kind of Chinese medicine preparation treating taste deficiency-heat type chronic gastritis | |
| CN106309770A (en) | Traditional Chinese medicine preparing for treating otitis media | |
| CN103372170A (en) | External traditional Chinese medicine for treating pyretic arthralgia, and preparation method thereof | |
| CN114796355A (en) | Pharmaceutical composition for treating diabetic dry eye | |
| CN107050358A (en) | A kind of Chinese medicine preparation for treating polymyalgia rheumatica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161221 |
|
| RJ01 | Rejection of invention patent application after publication |